Oncology

Therapeutics, diagnostics and evidence shaping cancer care.

Caloric Restriction Triggers Distinct Metabolic Regulation vs Fasting-Refeeding

Cell Press study describes anticipatory metabolic regulation as a key reason caloric restriction produces a different metabolic state than fasting-refeeding cycles.

By Dr. Revathy Mohan V.R., MBBS · Oct 23, 2026 · 5 min read

Oncology·Cancer Cell

Mitochondria-Targeted Tetraoxanes Drive Ferroptosis in Tumor Cells

Cell Press reports that mitochondria-targeted tetraoxanes trigger lipid peroxidation, inducing ferroptosis and suppressing tumor growth in cancer models.

Oct 23, 2026

Oncology·Cancer Cell

CFM-GP models gene perturbation responses across cell types

A conditional flow-matching model predicted gene perturbation effects across cell types, improving accuracy, alignment, and cross-species generalization.

Oct 23, 2026

Oncology·Cancer Cell

p63 and p73 drive cutaneous squamous cell carcinoma through EGFR signaling

A Cell Press study links p63 and p73 to cutaneous squamous cell carcinoma through convergent control of EGFR…

Oct 23, 2026

Oncology·Cancer Cell

Cancer diagnosis and treatment shift toward enabling technologies

A 2026 oncology review reframes cancer care around liquid biopsy, AI, spatial biology, vaccination, and next-generation immunotherapies.

Oct 23, 2026

Oncology·Cancer Cell

Cancer-Associated Fibroblasts Drive GI Cancer Metastasis, Review Finds

Review details how cancer-associated fibroblasts promote gastrointestinal metastasis through matrix remodeling, immune suppression, and therapy resistance.

Oct 23, 2026

Oncology·Cancer Cell

Nanomedicine Advances Targeted Phototherapy in Head and Neck Cancer

A review of nanomedicine-based photodynamic and photothermal therapy in head and neck cancer, including combination strategies and translation…

Oct 23, 2026

Oncology·Front Immunol

TTFields Phase 2 Study in Unresectable Gastric and GEJ Adenocarcinoma

Phase 2 pilot study tested TTFields with oxaliplatin and capecitabine, with or without trastuzumab, in first-line unresectable gastric…

Oct 23, 2026

Oncology·Front Immunol

CAR-T and CAR-NK Targets Gain Ground in Gastrointestinal Cancers

A Frontiers review tracks CAR-T and CAR-NK targets in GI malignancies, led by CLDN18.2 and early signals in…

Oct 23, 2026

Oncology·Eur Urol

FGFR3 Testing in Urothelial Carcinoma: Best Practices and Reporting

European Urology Oncology expert guidance outlines when to test FGFR3 in metastatic urothelial carcinoma and how to report…

Oct 23, 2026

Oncology

Therapeutics, diagnostics and evidence shaping cancer care.

In Brief The 5-minute rounds

New hypertension guideline lowers the treatment threshold to 130/80 mm Hg.
Phase 3 GLP-1 trial reports a 20% cut in major adverse cardiac events.
FDA clears a next-generation CAR-T therapy for relapsed lymphoma.
Meta-analysis links early mobilisation to shorter ICU length of stay.
Rapid guidance broadens empiric antibiotics for suspected sepsis.